Whereas in DM settings, SGLT2 inhibitors are usually combined with metformin [128], in non-diabetic CKD, it is recommended to combine SGLT2 inhibition with RAAS blockade, wherever it is indicated and tolerated [126]. Here, SLC5A2 is linked to chronic kidney disease.